Search results for "microbiology"

showing 10 items of 7546 documents

Lactobacillus plantarum LUHS135 and paracasei LUHS244 as functional starter cultures for the food fermentation industry: Characterisation, mycotoxin-…

2018

Abstract Lactobacillus plantarum LUHS135 and Lactobacillus paracasei LUHS244 from fermented cereals were isolated and their properties (carbohydrate metabolism, gas production, ability to survive at a low pH values, growth performance at different temperatures, antimicrobial properties against Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, Salmonella enterica, Corynebacter spp, Klebsiella pneomoniae, Enterococcus faecalis, Bacillus cereus, Proteus mirabilis, Clostridium spp., Streptococcus spp., resistance to antibiotics, and reducing properties for aflatoxin B1, ochratoxin A, HT-2 toxin, T-2 toxin, zearalenone) were evaluated. Also, the possibilities to use dairy by-produ…

0301 basic medicineOchratoxin AbiologyLactobacillus paracaseiChemistry030106 microbiologyBacillus cereusfood and beverages04 agricultural and veterinary sciencesbiology.organism_classification040401 food scienceEnterococcus faecalis03 medical and health scienceschemistry.chemical_compound0404 agricultural biotechnologyYeast extractFermentationLactobacillus plantarum Lactobacillus paracasei Antimicrobial activity Resistance to antibiotics Mycotoxins Whey EncapsulationFood scienceMycotoxinLactobacillus plantarumFood Science
researchProduct

Comparative evaluation of antimicrobial efficacy of three herbal irrigants in reducing intracanal E. faecalis populations: An in vitro study

2016

Background: The present study aimed to evaluate the intracanal bacterial reduction promoted by chemomechanical preparation using three different herbal extracts named Ocimum sanctum (OS), Cinnamomum zeylanicum (CZ), Syzygium aromaticum (SA) against Enterococcus faecalis. Material and Methods: Root canals from extracted teeth were contaminated with Enterococcus faecalis ATCC 29212 for 7 days and then randomly distributed into 3 experimental groups of 10 teeth each: which includes conventional irrigation with OS, CZ and SA. The control groups included 5 teeth each consisting of NaOCl (positive control) and distilled water (negative control). Samples taken before and after chemomechanical proc…

0301 basic medicineOdontologíaEnterococcus faecalisOperative Dentistry and EndodonticsMicrobiologyComparative evaluation03 medical and health sciences0302 clinical medicineMedicineIn vitro studyGeneral DentistrybiologyTraditional medicinebusiness.industryResearch030206 dentistry:CIENCIAS MÉDICAS [UNESCO]Antimicrobialbiology.organism_classificationOcimumCiencias de la saludCinnamomum zeylanicum030104 developmental biologyDistilled waterSyzygiumUNESCO::CIENCIAS MÉDICASbusinessJournal of Clinical and Experimental Dentistry
researchProduct

Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART

2018

Objectives We evaluated the association between pre-ART HIV DNA and HIV-infected participant characteristics at baseline as well as with their response to first-line ART. Methods Four hundred and thirty-three patients from the ICONA cohort, starting first-line ART after the year 2000, were analysed. Pre-ART HIV DNA was quantified with the modified COBAS TaqMan HIV-1 Test and normalized by CD4+ T cells. Linear correlation between pre-ART HIV DNA and other continuous markers (HIV RNA, CD4 count, markers of inflammation and coagulation) at baseline was evaluated by means of Pearson correlation coefficient and a linear regression model. Survival analyses and Cox regression models were used to s…

0301 basic medicineOncologyCD4-Positive T-LymphocytesMaleHIV InfectionsSettore MED/07chemistry.chemical_compoundHIV InfectionPharmacology (medical)ViralProspective StudiesProspective cohort studyAntiinfective agentAdult; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; DNA Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Viral LoadMiddle AgedViral LoadvirologyHIV CD4Stavudinemedicine.anatomical_structureInfectious DiseasesTreatment Outcomehiv-1 t-lymphocytes virology blood hiv rna hiv dnaAnti-Retroviral AgentsCD4-Positive T-Lymphocyteblood hiv rnaCohorthiv dnaFemaleSurvival AnalysiViral loadARTHumanMicrobiology (medical)Adultmedicine.medical_specialtyAntiretroviral Therapy CD4 Lymphocyte Count StavudineT cellAntiretroviral TherapySettore MED/17 - MALATTIE INFETTIVENO03 medical and health sciencesInternal medicinemedicineHumanst-lymphocytesSurvival analysisPharmacologybusiness.industryProportional hazards modelHIVDNASurvival AnalysisCD4 Lymphocyte CountProspective Studie030104 developmental biologychemistryDNA ViralHIV-1Anti-Retroviral AgentbusinessDNA
researchProduct

Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma

2018

Current treatment options for advanced and recurrent head and neck squamous cell carcinoma (HNSCC) enclose radiation and chemo-radiation approaches with or without surgery. While platinum-based chemotherapy regimens currently represent the gold standard in terms of efficacy and are given in the vast majority of cases, new chemotherapy regimens, namely immunotherapy are emerging. However, the response rates and therapy resistance mechanisms for either chemo regimen are hard to predict and remain insufficiently understood. Broad variations of chemo and radiation resistance mechanisms are known to date. This study describes the development of a standardized, high-throughput in vitro assay to a…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyGeneral Chemical Engineeringmedicine.medical_treatmentCell Culture TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences3D cell culture0302 clinical medicineInternal medicinemedicineCarcinomaHumansPrecision MedicineChemotherapyGeneral Immunology and MicrobiologySquamous Cell Carcinoma of Head and Neckbusiness.industryGeneral NeuroscienceHead and neck cancerImmunotherapymedicine.diseaseHead and neck squamous-cell carcinoma3. Good healthRegimen030104 developmental biologyHead and Neck Neoplasms030220 oncology & carcinogenesisCarcinoma Squamous CellPersonalized medicinebusinessJournal of Visualized Experiments
researchProduct

Decreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test, Latvia

2016

This test decreased time to treatment initiation by 66%–84%.

0301 basic medicineOncologyMaleEpidemiologylcsh:Medicine0302 clinical medicine1108 Medical MicrobiologyTuberculosis Multidrug-Resistant030212 general & internal medicinebacteriaDecreased Time to Treatment Initiation for Multidrug-Resistant Tuberculosis Patients after Use of Xpert MTB/RIF Test Latviabiologytime to treatment initiationDrug Resistance MicrobialMiddle Agedmultidrug-resistant tuberculosisRifampin resistanceInfectious Diseases1117 Public Health And Health ServicesTuberculosis Multidrug-Resistant/diagnosisFemaleRifampinLife Sciences & BiomedicineMicrobiology (medical)Adultmedicine.medical_specialtyTuberculosisAdolescentpulmonary030106 microbiologyXpert MTB/RIFImmunologyTime to treatmentMicrobiologylcsh:Infectious and parasitic diseasesTime-to-TreatmentMycobacterium tuberculosismolecular diagnostics03 medical and health sciencesYoung AdultAntibiotic resistancemultidrug resistanceInternal medicinemedicineHumanslcsh:RC109-216Multivariable modelantimicrobial resistanceTuberculin testAntibiotics AntitubercularScience & Technologybusiness.industryTuberculin TestResearchlcsh:RMycobacterium tuberculosis/drug effects1103 Clinical SciencesMycobacterium tuberculosisbiology.organism_classificationmedicine.diseaseAntibiotics Antitubercular/pharmacologyLatviatuberculosis and other mycobacteriaMultiple drug resistanceMODELTuberculin Test/methodsbusinessRifampin/pharmacologyMDR TB
researchProduct

The effectiveness of combination chemotherapy with cisplatinum and etoposide in the treatment of advanced non-small cell lung cancer.

1989

Twenty-one patients with histologically proven advanced or disseminated non-small cell lung cancer were treated with cisplatinum 80 mg/m2 i.v. day 1 and etoposide (VP16) 80 mg/m2 i.v. day 1- greater than 3.15 patients were evaluable for response. One patient (6.6%) achieved a complete response, 4 (26.7%) a partial response and 6 (40.0%) a stabilization of disease. Four patients (26.7%) progressed. An improvement in performance status was obtained in more than 50% of cases. Responders had a mean survival of 345 + days, while non-responders 191.7 days. The treatment was generally well tolerated. In our opinion this combination regimen offers good palliation for patients affected by advanced a…

0301 basic medicineOncologyMalemedicine.medical_specialtyLung Neoplasms030106 microbiologyDisease03 medical and health sciences0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansPharmacology (medical)Lung cancerEtoposideAgedEtoposidePharmacologyCisplatinPerformance statusbusiness.industryCombination chemotherapyMiddle Agedmedicine.diseaseRegimenInfectious DiseasesOncology030220 oncology & carcinogenesisFemaleNon small cellCisplatinbusinessmedicine.drugJournal of chemotherapy (Florence, Italy)
researchProduct

Treatment of invasive fungal diseases in cancer patients—Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German …

2020

Background Invasive fungal diseases remain a major cause of morbidity and mortality in cancer patients undergoing intensive cytotoxic therapy. The choice of the most appropriate antifungal treatment (AFT) depends on the fungal species suspected or identified, the patient's risk factors (eg length and depth of granulocytopenia) and the expected side effects. Objectives Since the last edition of recommendations for 'Treatment of invasive fungal infections in cancer patients' of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) in 2013, treatment strategies were gradually moving away from solely empirical therapy of presumed or possib…

0301 basic medicineOncologymedicine.medical_specialtyAntifungal Agents030106 microbiologyMedizinDermatologyNeutropeniaAspergillosis030207 dermatology & venereal diseases03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineHumansHematologybusiness.industryMucormycosisCancerGeneral MedicineGuidelineEvidence-based medicineHematologymedicine.diseaseClinical trialInfectious DiseasesHematologic NeoplasmsPractice Guidelines as TopicbusinessInvasive Fungal InfectionsAgranulocytosis
researchProduct

5-Fluorouracil and recombinant alpha interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study

1990

A dose optimization study was carried out with the aim of identifying the maximally tolerated dose of recombinant alpha interferon-2a (raIFN-2a) in combination with 5-fluorouracil (5FU). 5FU was given at the dose of 750 mg/m2 over a 4-hour infusion on day 1- - greater than 5 followed by 750 mg/m2 weekly i.v. bolus. Recombinant aIFN-2a was started at 3 x 10(6) IU subcutaneously three times/week. 12 patients with advanced colorectal carcinoma were included in the study. 10 patients had previously received chemotherapy for advanced disease. Severe fatigue, most likely attributable to rIFN, was the dose-limiting toxicity. The dosage of raIFN-2a could not be further escalated above 12 x 10(6) IU…

0301 basic medicineOncologymyalgiamedicine.medical_specialtymedicine.medical_treatmentInjections Subcutaneous030106 microbiologyAlpha interferonInterferon alpha-2Gastroenterology03 medical and health sciences0302 clinical medicineBolus (medicine)Internal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansPharmacology (medical)PharmacologyChemotherapyPerformance statusbusiness.industryCarcinomaInterferon-alphamedicine.diseaseRecombinant ProteinsInfectious DiseasesOncologyFluorouracil030220 oncology & carcinogenesisToxicityFluorouracilmedicine.symptombusinessColorectal Neoplasmsmedicine.drug
researchProduct

A practical method for barcoding and size-trimming PCR templates for amplicon sequencing

2016

Sample barcoding facilitates the analysis of tens or even hundreds of samples in a single next-generation sequencing (NGS) run, but more efficient methods are needed for high-throughput barcoding and size-trimming of long PCR products. Here we present a two-step PCR approach for barcoding followed by pool shearing, adapter ligation, and 5′ end selection for trimming sets of DNA templates of any size. Our new trimming method offers clear benefits for phylogenetic studies, since targeting exactly the same region maximizes the alignment and enables the use of operational taxonomic unit (OTU)-based algorithms.

0301 basic medicineOperational taxonomic unitComputer science030106 microbiologyLong pcrComputational biologyPolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyDNA sequencinglaw.invention03 medical and health scienceslawDNA Barcoding TaxonomicGenomic libraryligationPolymerase chain reactionGene Libraryta1184ta1182High-Throughput Nucleotide SequencingDNAMolecular biologyprimer030104 developmental biologyTemplatePCRpolyclonalityAmplicon sequencingTrimmingnext-generation sequencingAlgorithmsBiotechnology
researchProduct

Consequences of organ choice in describing bacterial pathogen assemblages in a rodent population

2017

SUMMARYHigh-throughput sequencing technologies now allow for rapid cost-effective surveys of multiple pathogens in many host species including rodents, but it is currently unclear if the organ chosen for screening influences the number and identity of bacteria detected. We used 16S rRNA amplicon sequencing to identify bacterial pathogens in the heart, liver, lungs, kidneys and spleen of 13 water voles (Arvicola terrestris) collected in Franche-Comté, France. We asked if bacterial pathogen assemblages within organs are similar and if all five organs are necessary to detect all of the bacteria present in an individual animal. We identified 24 bacteria representing 17 genera; average bacterial…

0301 basic medicineOperational taxonomic unitMESH: Sequence Analysis DNAEpidemiologyMESH : PrevalenceMESH : Tissue DistributionRodent DiseasesRNA Ribosomal 16Sbacterial pathogensPrevalenceMESH : DNA BacterialTissue DistributionMESH: AnimalsPathogen[SDV.EE]Life Sciences [q-bio]/Ecology environmenteducation.field_of_studybiologyEcologyArvicolinaeMicrobiotaMESH : Rodent Diseases3. Good healthMESH: RNA Ribosomal 16SInfectious DiseasesArvicolinaeFrancerodent-borne pathogenDNA Bacterial030106 microbiologyPopulationShort ReportZoology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesAnimalsMESH: MicrobiotaMESH : BacteriaMESH: Tissue DistributionArvicola terrestriseducationMESH : FranceMESH: Prevalence[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBacteriaHost (biology)tissue selectionBacteria PresentSequence Analysis DNAMESH: Arvicolinaebiology.organism_classificationMESH: DNA BacterialMESH: FranceMESH : ArvicolinaeMESH : RNA Ribosomal 16SMESH: BacteriaHigh-Throughput Sequencing030104 developmental biologyMESH : MicrobiotaSpecies richnessMESH: Rodent DiseasesMESH : Animals[SDE.BE]Environmental Sciences/Biodiversity and EcologyBacteriaMESH : Sequence Analysis DNA
researchProduct